Insilico Medicine and ChemDiv form a strategic drug discovery service alliance
SanDiego (CA) - Insilico Medicine and ChemDiv, Inc. launched a new strategiccollaboration to provide certain pharmaceutical and biotechnology companieswith end-to-end drug discovery solutions. This collaboration combines the mostadvanced artificial intelligence (AI) techniques with apremium integrated drug discovery shared risk platform. The combination of complementary capabilities introducesa new value for companies working in the field, giving them a powerful tool forquick, cost-effective therapeutic product development.
“We’repleased to partner with ChemDiv, the leading discovery contract researchorganization, which built a massive repository of small molecules,” said AlexZhavoronkov, PhD., CEO of Insilico Medicine. “ChemDiv has had a number ofhighly successful collaborations with pharmaceutical companies in multipletherapeutic areas, moving their discoveries from theunique chemistry idea into the clinic. Together we willimprove the novelty, quality andefficiency of preclinical drug discovery and bring our technology andexperience to other biotech and pharma partners.”
SergeyBugrov, Executive Director of ChemDiv said: “With Insilico Medicine’s AItechnology, previously intractable targets could become viable therapeutic opportunities andthe time for preclinical drug discovery could dramatically shorten. Our joint goal is to generate new leads against identified andpredicted novel targets. Itallows us to continuously deliver great service to our partners and help themdevelop effective treatments for unmet medical needs.”
Thecommercial terms will include technology access, success focused milestone androyalties.
ChemDiv is a recognized global leader in drugdiscovery solutions. Over the past 29 years ChemDiv has delivered hundreds ofleads, drug candidates and new drugs in the area of CNS, oncology, virology,inflammation, cardiometabolic and immunology, to pharma, biotech and academicpartners around the globe. [www.chemdiv.com]
Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with offices in six countries and regions. The Company was the first to apply the generative adversarial networks (GANs) and reinforcement learning (RL) to generate new molecular structures with the specified parameters in 2015. In addition to collaborating with large pharmaceutical companies, Insilico Medicine is also pursuing internal drug discovery programs in different disease areas and anti-aging fields. Recently, Insilico Medicine published some of the resuts in Nature Biotechnology, and secured $37 million in series B funding. Website http://insilico.com/
For further information, images or interviews, please contact:
Insilico Medicine:Klug Gehilfe, firstname.lastname@example.org
ChemDiv Inc.: Ron Demuth, email@example.com